3 results on '"Kleine‐Tebbe, Jörg"'
Number of results to display per page
Search Results
2. International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics
- Author
-
Oliver Pfaar, Thomas Werfel, Linda Cox, Antonella Muraro, Ruby Pawankar, James L. Sublett, Cezmi A. Akdis, Jörg Kleine-Tebbe, Bryan Martin, Moises A. Calderon, Ronald van Ree, George Du Toit, Luo Zhang, Robyn E O'Hehir, Sergio Bonini, Gideon Lack, Mübeccel Akdis, Hugh A. Sampson, Ioana Agache, Pascal Demoly, Désirée Larenas, Walter Canonica, Michael Levin, A. Wesley Burks, Roy Gerth van Wijk, Marek Jutel, Kazunari Sugita, Harald Nelson, A. J. Frew, Internal Medicine, University of Zurich, Jutel, Marek, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Experimental Immunology, Agache, Ioana, Bonini, Sergio, Burks, A. Wesley, Calderon, Moise, Canonica, Walter, Cox, Linda, Demoly, Pascal, Frew, Antony J., O'Hehir, Robyn, Kleine Tebbe, Jörg, Muraro, Antonella, Lack, Gideon, Larenas, Désirée, Levin, Michael, Martin, Bryan L., Nelson, Harald, Pawankar, Ruby, Pfaar, Oliver, Van Ree, Ronald, Sampson, Hugh, Sublett, James L., Sugita, Kazunari, Du Toit, George, Werfel, Thoma, Gerth Van Wijk, Roy, Zhang, Luo, Akdis, Mübeccel, Akdis, Cezmi A., Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, and Université de Montpellier (UM)
- Subjects
0301 basic medicine ,Allergy ,Standardization ,Cost effectiveness ,Cost-Benefit Analysis ,Alternative medicine ,cost-effectivene ,0302 clinical medicine ,pharmacoeconomics ,10183 Swiss Institute of Allergy and Asthma Research ,Immunology and Allergy ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,International consensus ,allergen standardization ,allergen vaccine ,allergy ,cost-effectiveness ,immunotherapy ,marketing authorization ,mechanisms ,regulatory authorities ,tolerance ,unmet needs ,media_common ,International consensu ,Allergen ,Medicine (all) ,unmet need ,3. Good health ,2723 Immunology and Allergy ,Human ,Allergen immunotherapy ,medicine.medical_specialty ,Consensus ,Immunology ,education ,mechanism ,Consensu ,610 Medicine & health ,Marketing authorization ,03 medical and health sciences ,Pharmacoeconomics ,Hypersensitivity ,Immune Tolerance ,medicine ,Humans ,media_common.cataloged_instance ,Economics, Pharmaceutical ,Cost-Benefit Analysi ,European union ,2403 Immunology ,business.industry ,Allergens ,medicine.disease ,pharmacoeconomic ,030104 developmental biology ,030228 respiratory system ,Desensitization, Immunologic ,Family medicine ,business ,regulatory authoritie - Abstract
International audience; This article continues the comprehensive international consensus (ICON) statement on allergen immunotherapy (AIT). The initial article also recently appeared in the Journal. The conclusions below focus on key mechanisms of AIT-triggered tolerance, requirements in allergen standardization, AIT cost-effectiveness, and regulatory guidance. Potential barriers to and facilitators of the use of AIT are described in addition to future directions. International allergy specialists representing the European Academy of Allergy and Clinical Immunology; the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma and Immunology; and the World Allergy Organization critically reviewed the existing literature and prepared this summary of recommendations for best AIT practice. The authors contributed equally and reached consensus on the statements presented herein.
- Published
- 2016
- Full Text
- View/download PDF
3. International consensus on allergy immunotherapy
- Author
-
A. J. Frew, Gideon Lack, George Du Toit, Oliver Pfaar, Cezmi A. Akdis, Alexandra F. Santos, Ruby Pawankar, Hugh A. Sampson, Pascal Demoly, Linda Cox, Harald Nelson, Michael Levin, Jörg Kleine-Tebbe, A. Wesley Burks, Moises A. Calderon, Ronald van Ree, Luo Zhang, Ioana Agache, Thomas Werfel, Marek Jutel, Antonella Muraro, Robin O'Hehir, Sergio Bonini, Walter Canonica, Roy Gerth van Wijk, Désirée Larenas, Jutel, Marek, Agache, Ioana, Bonini, Sergio, Burks, A. Wesley, Calderon, Moise, Canonica, Walter, Cox, Linda, Demoly, Pascal, Frew, Antony J., O'Hehir, Robin, Kleine Tebbe, Jörg, Muraro, Antonella, Lack, Gideon, Larenas, Désirée, Levin, Michael, Nelson, Harald, Pawankar, Ruby, Pfaar, Oliver, Van Ree, Ronald, Sampson, Hugh, Santos, Alexandra F., Du Toit, George, Werfel, Thoma, Gerth Van Wijk, Roy, Zhang, Luo, Akdis, Cezmi A., Erasmus MC other, Internal Medicine, Clinical Genetics, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Experimental Immunology, and University of Zurich
- Subjects
Allergy ,medicine.medical_treatment ,International Cooperation ,Dermatitis ,Desensitization ,medicine.disease_cause ,Allergen ,Immunologic ,10183 Swiss Institute of Allergy and Asthma Research ,Immunology and Allergy ,Rhinitis ,Desensitization (medicine) ,allergen vaccine ,allergic rhinitis ,allergy ,asthma ,atopic dermatitis ,food allergy ,immunotherapy ,International consensus ,Adjuvants, Immunologic ,Allergens ,Dermatitis, Atopic ,Desensitization, Immunologic ,Food Hypersensitivity ,Humans ,Immune Tolerance ,Practice Guidelines as Topic ,Rhinitis, Allergic ,Consensus ,Immunology ,Medicine (all) ,biology ,International consensu ,Atopic dermatitis ,2723 Immunology and Allergy ,allergic rhiniti ,Human ,atopic dermatiti ,Allergen immunotherapy ,medicine.medical_specialty ,610 Medicine & health ,Consensu ,Atopic ,Allergic ,Food allergy ,International consensus allergy immunotherapy allergen vaccine allergic rhinitis asthma food allergy atopic dermatitis ,medicine ,Adjuvants ,Intensive care medicine ,Asthma ,House dust mite ,2403 Immunology ,business.industry ,biology.organism_classification ,medicine.disease ,respiratory tract diseases ,business - Abstract
Allergen immunotherapy (AIT) has been used to treat allergic disease since the early 1900s. Despite numerous clinical trials and meta-analyses proving AIT efficacious, it remains underused and is estimated to be used in less than 10% of patients with allergic rhinitis or asthma worldwide. In addition, there are large differences between regions, which are not only due to socioeconomic status. There is practically no controversy about the use of AIT in the treatment of allergic rhinitis and allergic asthma, but for atopic dermatitis or food allergy, the indications for AIT are not well defined. The elaboration of a wider consensus is of utmost importance because AIT is the only treatment that can change the course of allergic disease by preventing the development of asthma and new allergen sensitizations and by inducing allergen-specific immune tolerance. Safer and more effective AIT strategies are being continuously developed both through elaboration of new allergen preparations and adjuvants and alternate routes of administration. A number of guidelines, consensus documents, or both are available on both the international and national levels. The international community of allergy specialists recognizes the need to develop a comprehensive consensus report to harmonize, disseminate, and implement the best AIT practice. Consequently, the International Collaboration in Asthma, Allergy and Immunology, formed by the European Academy of Allergy and Clinical Immunology; the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma & Immunology; and the World Allergy Organization, has decided to issue an international consensus on AIT.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.